Affinity Asset Advisors’s Silence Therapeutics SLN Stock Holding History

Affinity Asset Advisors’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.92M	Buy	+450,000	New	+$5.48M	0.2%	76

Other funds holding SLN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Affinity Asset Advisors's SLN Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Silence Therapeutics (SLN) in Q3 2026: 450,000 shares worth $4.92M. The stake represents 0.2% of the portfolio and ranks #76 among its holdings.

43 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

Affinity Asset Advisors held 450,000 shares of Silence Therapeutics worth $4.92M as of Q3 2026.
Silence Therapeutics was a new Affinity Asset Advisors position in Q3 2026.
Silence Therapeutics made up 0.2% of Affinity Asset Advisors's portfolio in Q3 2026, its #76 holding.
43 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.